MELANOMA: tratamiento de primera línea - page 5

Pembrolizumab Versus Ipilimumab For Advanced Melanoma: <br />Final Overall Survival Analysis of KEYNOTE-006

Presented By Jacob Schachter at 2016 ASCO Annual Meeting

35% BRAF mutados

(17% tto iBRAF previo)

29% LDH elevada

81% PD-L1 positivo

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1,2,3,4 6,7,8,9,10,11,12,13,14,15,...37